New cancer drug ZN-c3 shows promise in early trial

NCT ID NCT04158336

Completed Disease control Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc Source: ClinicalTrials.gov ↗

First seen Mar 28, 2026 · Last updated May 19, 2026 · Updated 11 times

Summary

This early-stage study tested a new drug, ZN-c3 (Azenosertib), in 274 adults with solid tumors. The main goals were to find a safe dose and see if the drug can shrink tumors. The study is now complete, and results will help decide if further testing is needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Site 0100

San Antonio, Texas, 78229, United States
Site 0101

Detroit, Michigan, 48201, United States
Site 0102

Tucson, Arizona, 85719, United States
Site 0103

Houston, Texas, 77030, United States
Site 0167

Newport Beach, California, 92663, United States
Site 0171

Chicago, Illinois, 60637, United States
Site 0173

New York, New York, 10029, United States
Site 0179

Pittsburgh, Pennsylvania, 15213, United States

Conditions

Explore the condition pages connected to this study.

SOLID TUMOR